The THINC-Integrated Tool (THINC-it) Screening Assessment for Cognitive Dysfunction

McIntyre, Roger S.; Best, Michael W.; Bowie, Christopher R.; Carmona, Nicole E.; Danielle, S.; Lee, Yena; Subramaniapillai, Mehala; Mansur, Rodrigo B.; Barry, Harry; Baune, Bernhard T.; Culpepper, Larry; Fossati, Philippe; Greer, Tracy L.; Harmer, Catherine J.; Klag, Esther; Lam, Raymond W.; Wittchen, H.‐U.; Harrison, John

doi:10.4088/jcp.16m11329

Cited by 117 publications

(107 citation statements)

References 40 publications

Supporting

Mentioning

104

Contrasting

Order By: Relevance

“…Most cognition assessment tools are too time-consuming for clinical use and many require professional interpretation, often with cost. The THINC-integrated tool (THINC-it) is an instrument with satisfactory psychometric properties whose administration is feasible in routine practice 104 . It has been validated both as a screening tool for cognitive impairment in depression and as a measure to detect change in cognition with treatment.…”

Section: Neurocognitionmentioning

confidence: 99%

The clinical characterization of the adult patient with depression aimed at personalization of management

et al. 2020

Self Cite

View full text Add to dashboard Cite

Depression is widely acknowledged to be a heterogeneous entity, and the need to further characterize the individual patient who has received this diagnosis in order to personalize the management plan has been repeatedly emphasized. However, the research evidence that should guide this personalization is at present fragmentary, and the selection of treatment is usually based on the clinician's and/or the patient's preference and on safety issues, in a trial‐and‐error fashion, paying little attention to the particular features of the specific case. This may be one of the reasons why the majority of patients with a diagnosis of depression do not achieve remission with the first treatment they receive. The predominant pessimism about the actual feasibility of the personalization of treatment of depression in routine clinical practice has recently been tempered by some secondary analyses of databases from clinical trials, using approaches such as individual patient data meta‐analysis and machine learning, which indicate that some variables may indeed contribute to the identification of patients who are likely to respond differently to various antidepressant drugs or to antidepressant medication vs. specific psychotherapies. The need to develop decision support tools guiding the personalization of treatment of depression has been recently reaffirmed, and the point made that these tools should be developed through large observational studies using a comprehensive battery of self‐report and clinical measures. The present paper aims to describe systematically the salient domains that should be considered in this effort to personalize depression treatment. For each domain, the available research evidence is summarized, and the relevant assessment instruments are reviewed, with special attention to their suitability for use in routine clinical practice, also in view of their possible inclusion in the above‐mentioned comprehensive battery of measures. The main unmet needs that research should address in this area are emphasized. Where the available evidence allows providing the clinician with specific advice that can already be used today to make the management of depression more personalized, this advice is highlighted. Indeed, some sections of the paper, such as those on neurocognition and on physical comorbidities, indicate that the modern management of depression is becoming increasingly complex, with several components other than simply the choice of an antidepressant and/or a psychotherapy, some of which can already be reliably personalized.

show abstract

Section: Neurocognitionmentioning

confidence: 99%

The clinical characterization of the adult patient with depression aimed at personalization of management

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…However, a comprehensive tool to assess cognitive deficits is lacking. The THINC-integrated tool (THINC-it) is a validated, computerized cognitive assessment system that screens both objective and subjective cognitive deficits in MDD [69]. Other validated tools used to assess objective and subjective cognitive impairment in MDD include the Screen for Cognitive Impairment in Psychiatry (SCIP-D) and the Cognitive Complaints in Bipolar Disorder Assessment (COBRA) [70].…”

Section: Depression In Psoriatic Arthritis Is Multi-dimensional With mentioning

confidence: 99%

Depression in Psoriatic Arthritis: Dimensional Aspects and Link with Systemic Inflammation

Mathew

Chandran

2020

Rheumatol Ther

View full text Add to dashboard Cite

Studying comorbidities in patients with psoriatic arthritis (PsA) provides a better understanding of the extended burden of the disease. Depression and anxiety are well recognized but understudied comorbidities in patients with PsA. The prevalence of depression is significantly higher in this patient population than in the general population, with far reaching consequences in terms of long-term quality of life. Over the past few years there has been an increasing interest in the link between inflammation and depression, with several novel studies being conducted. Recent evidence suggests a significant improvement of depression in PsA patients treated with biologic disease-modifying anti-rheumatic drugs (bDMARDs) as compared to conventional DMARDs. Depression in PsA is multidimensional, with recognized phenotypes, including cognitive disorder, alexithymia and anhedonia. The paucity of standardized, validated tools to screen these dimensional phenotypes remains an unmet need. Prevalence studies on depression in patients with PsA, mostly based on patient-reported outcomes, are only able to highlight the tip of the iceberg. A comprehensive, multidisciplinary approach addressing the subdomains of depression is imperative for a better understanding of depression in PsA patients, as well as to find a way forward for improving their quality of life. In this scoping review, we explore existing evidence on the burden of depression in PsA patients, the link between inflammation and depression in these patients and the screening tools used to evaluate the subdomains of depression.

show abstract

“…In the last years, the mobile, self‐administered assessment of cognition has slowly started to make ground, but not many validation studies have yet been done. The THINC‐integrated tool (THINC‐it) cognitive screener app (McIntyre et al, ) has recently been validated for subjects with depression. In the current paper, we study an online and patient‐administered instrument for patients with varying psychiatric disorders, the MyCQ.…”

Section: Introductionmentioning

confidence: 99%

“…In the last years, the mobile, self-administered assessment of cognition has slowly started to make ground, but not many validation studies have yet been done. The THINC-integrated tool (THINC-it) cognitive screener app (McIntyre et al, 2017) has recently been validated for subjects with depression.…”

mentioning

confidence: 99%

The validation of a new online cognitive assessment tool: The MyCognition Quotient

Domen

Weijer

Jaspers

et al. 2019

Int J Methods Psych Res

View full text Add to dashboard Cite

ObjectivesCognitive impairment affects many psychiatric patients, influences daily functioning, and should be an important treatment focus. Assessment of cognitive status is crucial in cognitive remediation studies. However, current test batteries have limitations. A new, online tool, the MyCognition Quotient (MyCQ), was developed to assess cognition within 30 min. We present the psychometric properties and aim to determine the validity of the MyCQ by comparing it with the Cambridge Neuropsychological Automated Test Battery (CANTAB).MethodsEighty‐seven patients diagnosed with obsessive compulsive disorder, schizophrenia/schizoaffective disorder, or major depressive disorder were included. Patients completed both the MyCQ and CANTAB.ResultsOur hypothesized domains of psychomotor speed, attention, episodic memory, working memory, and executive functioning were confirmed by principal component analysis. The MyCQ total score correlated highly with the CANTAB total score. The MyCQ domains of psychomotor speed, attention, and episodic memory showed moderate to high correlations with corresponding CANTAB domains. Working memory and executive functioning had limited divergent validity.ConclusionThe MyCQ appears to be a promising instrument for assessing cognition online within a mixed psychiatric population. It is cost‐efficient, easily administered, and usable in different psychiatric populations, which makes it a good candidate for both clinical and community studies.

show abstract

The THINC-Integrated Tool (THINC-it) Screening Assessment for Cognitive Dysfunction

Abstract: ClinicalTrials.gov identifier: NCT02508493.

Cited by 117 publications

References 40 publications

The clinical characterization of the adult patient with depression aimed at personalization of management

The clinical characterization of the adult patient with depression aimed at personalization of management

Depression in Psoriatic Arthritis: Dimensional Aspects and Link with Systemic Inflammation

The validation of a new online cognitive assessment tool: The MyCognition Quotient

Contact Info

Product

Resources

About